TRIPHASIC CONTRACEPTIVE METHOD AND KIT COMPRISING A COMBINATION OF A PROGESTIN AND ESTROGEN

摘要

This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days: a first phase combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg νg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days; a second phase combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg νg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days; a third phase combination of a progestin at a daily dosage of 40-500 νg trimegestone, 250 νg - 4 mg dienogest, or 250 νg - 4 mg νg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 νg ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days; and an estrogen phase estrogen at a daily dosage equivalent in estrogenic activity to 5-20 νg ethinyl estradiol, for 3-5 days beginning on the day immediately following the last day of administration of the third phase combination, wherein the same dosage of the estrogen is administered in each of the 3-5 days, provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.